Comparison of One-Year Outcomes in Patients >75 Versus <=75 Years With Coronary Artery Disease Treated With COMBO Stents (From The MASCOT Registry)
2020
Abstract
Older patients who undergo coronary interventions are at greater risk of ischemic events and less likely to tolerate prolonged dual antiplatelet therapy (DAPT) due to bleeding risk. The COMBO biodegradable polymer sirolimus-eluting stent promotes rapid endothelialization through endothelial progenitor cell capture technology which may be advantageous in elderly patients.
We compared 1-year clinical outcomes and DAPT cessation events in patients >75 versus 75 years and 72% (n = 2,135) patients 75 years versus 3.1% patients 75 years treated with COMBO stents had similar TLF but significantly greater incidence of bleeding than younger patients and DAPT cessation in one-third of patients over 1 year. (C) 2020